Analysis of the Relationship Between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review

Overview

Journal Parkinsons Dis

Publisher Wiley

Date 2019 Dec 25

PMID 31871617

Citations 31

Authors

Fauze Camargo Maluf

David Feder

Alzira Alves de Siqueira Carvalho

Affiliations

Soon will be listed here.

Abstract

In the early sixties, a discussion started regarding the association between Parkinson's disease (PD) and type II diabetes mellitus (T2DM). Today, this potential relationship is still a matter of debate. This review aims to analyze both diseases concerning causal relationships and treatments. A total of 104 articles were found, and studies on animal and "in vitro" models showed that T2DM causes neurological alterations that may be associated with PD, such as deregulation of the dopaminergic system, a decrease in the expression of peroxisome proliferator-activated receptor-gamma coactivator-1 (), an increase in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 (PED/PEA-15), and neuroinflammation, as well as acceleration of the formation of alpha-synuclein amyloid fibrils. In addition, clinical studies described that Parkinson's symptoms were notably worse after the onset of T2DM, and seven deregulated genes were identified in the DNA of T2DM and PD patients. Regarding treatment, the action of antidiabetic drugs, especially incretin mimetic agents, seems to confer certain degree of neuroprotection to PD patients. In conclusion, the available evidence on the interaction between T2DM and PD justifies more robust clinical trials exploring this interaction especially the clinical management of patients with both conditions.

Citing Articles

Insulin and TLR4 Inhibitor Improve Motor Impairments in a Rat Model of Parkinson's Disease.

Hemmati F, Valian N, Ahmadiani A, Mohamed Z, Azman Ali R, Mohamed Ibrahim N Iran J Pharm Res. 2025; 23(1):e144200.

PMID: 39830652 PMC: 11742580. DOI: 10.5812/ijpr-144200.

Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trial.

Yulug B, Altay O, Li X, Hanoglu L, Cankaya S, Velioglu H Brain Commun. 2025; 7(1):fcae478.

PMID: 39816194 PMC: 11733689. DOI: 10.1093/braincomms/fcae478.

Insulin Resistance Is a Modifying Factor for Parkinson's Disease.

Zagare A, Hemedan A, Almeida C, Frangenberg D, Gomez-Giro G, Antony P Mov Disord. 2024; 40(1):67-76.

PMID: 39499190 PMC: 11752983. DOI: 10.1002/mds.30039.

Ferroptosis-A Shared Mechanism for Parkinson's Disease and Type 2 Diabetes.

Duta C, Muscurel C, Dogaru C, Stoian I Int J Mol Sci. 2024; 25(16).

PMID: 39201524 PMC: 11354749. DOI: 10.3390/ijms25168838.

Diabetes and Parkinson's Disease: Understanding Shared Molecular Mechanisms.

Konig A, Outeiro T J Parkinsons Dis. 2024; 14(5):917-924.

PMID: 38995799 PMC: 11307096. DOI: 10.3233/JPD-230104.

References

Martinez A, Morgese M, Pisanu A, Macheda T, Paquette M, Seillier A . Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats. Neurobiol Dis. 2014; 74:295-304. PMC: 4323744. DOI: 10.1016/j.nbd.2014.11.024. View

Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V . Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A. 2005; 102(52):19126-31. PMC: 1323177. DOI: 10.1073/pnas.0508215102. View

Lu J, Randell E, Han Y, Adeli K, Krahn J, Meng Q . Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin Biochem. 2010; 44(4):307-11. DOI: 10.1016/j.clinbiochem.2010.11.004. View

Oueslati A, Ximerakis M, Vekrellis K . Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation. Exp Neurobiol. 2014; 23(4):324-36. PMC: 4276803. DOI: 10.5607/en.2014.23.4.324. View

Choi J, Park C, Jeong J . AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biochem Biophys Res Commun. 2009; 391(1):147-51. DOI: 10.1016/j.bbrc.2009.11.022. View

Gehlert D, Robertson D . ATP sensitive potassium channels: potential drug targets in neuropsychopharmacology. Prog Neuropsychopharmacol Biol Psychiatry. 1994; 18(7):1093-102. DOI: 10.1016/0278-5846(94)90113-9. View

Karolina D, Armugam A, Tavintharan S, Wong M, Lim S, Sum C . MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011; 6(8):e22839. PMC: 3148231. DOI: 10.1371/journal.pone.0022839. View

van Harten B, de Leeuw F, Weinstein H, Scheltens P, Biessels G . Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006; 29(11):2539-48. DOI: 10.2337/dc06-1637. View

10.

Nelson P, Smith C, Abner E, Schmitt F, Scheff S, Davis G . Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta. 2008; 1792(5):454-69. PMC: 2834412. DOI: 10.1016/j.bbadis.2008.08.005. View

11.

Yue X, Li H, Yan H, Zhang P, Chang L, Li T . Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies. Medicine (Baltimore). 2016; 95(18):e3549. PMC: 4863785. DOI: 10.1097/MD.0000000000003549. View

12.

Di Monte D . The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?. Lancet Neurol. 2003; 2(9):531-8. DOI: 10.1016/s1474-4422(03)00501-5. View

13.

Crestanello J, Babsky A, Doliba N, Niibori K, Osbakken M, Whitman G . Opening of potassium channels protects mitochondrial function from calcium overload. J Surg Res. 2000; 94(2):116-23. DOI: 10.1006/jsre.2000.5979. View

14.

Colca J, McDonald W, Waldon D, Leone J, Lull J, Bannow C . Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab. 2003; 286(2):E252-60. DOI: 10.1152/ajpendo.00424.2003. View

15.

Takasaki S . Mitochondrial haplogroups associated with Japanese centenarians, Alzheimer's patients, Parkinson's patients, type 2 diabetic patients and healthy non-obese young males. J Genet Genomics. 2009; 36(7):425-34. DOI: 10.1016/S1673-8527(08)60132-0. View

16.

Pressley J, Louis E, Tang M, Cote L, Cohen P, Glied S . The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003; 60(1):87-93. DOI: 10.1212/wnl.60.1.87. View

17.

De Pablo-Fernandez E, Breen D, Bouloux P, Barker R, Foltynie T, Warner T . Neuroendocrine abnormalities in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2016; 88(2):176-185. DOI: 10.1136/jnnp-2016-314601. View

18.

Santiago J, Scherzer C, Potashkin J . Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS One. 2014; 9(10):e109042. PMC: 4184821. DOI: 10.1371/journal.pone.0109042. View

19.

Martin-Montalvo A, Mercken E, Mitchell S, Palacios H, Mote P, Scheibye-Knudsen M . Metformin improves healthspan and lifespan in mice. Nat Commun. 2013; 4:2192. PMC: 3736576. DOI: 10.1038/ncomms3192. View

20.

Perry T, Lahiri D, Chen D, Zhou J, Shaw K, Egan J . A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002; 300(3):958-66. DOI: 10.1124/jpet.300.3.958. View